Ces Urol 2010, 14(3):129-138 | DOI: 10.48095/cccu2010025

Molecular characteristics of clinically significant prostate carcinoma

Marek Schmidt1, Ladislav Jarolím1, Jan Soukup2, Jaroslav Mareš3
1 Urologická klinika 2. LF UK a FN Motol, Praha
2 Ústav klinické patologie 2. LF UK a FN Motol, Praha
3 Ústav biologie a lékařské genetiky 2. LF UK a FN Motol, Praha

In last years, diagnostics and treatment of localized prostate cancer were improved. Introduction of a new methods caused rising detection of patients, for whom, due to the age or comorbidities, radical therapy is with relative benefit. Decision, whether single cancer is for concrete patient clinically significant or not, is often complicated. Common prognostic factors are not able to solve this problem. Familiar and hereditary prostate cancer definition leads modern scientific research to detection of genetic dispositions of a single patient to develop a disease. There were detected a number of candidate genes and genomic areas, where alterations or polymorphisms are frequently present in patients with prostate cancer or in prostate cancer families. Detail analysis of genetic alterations and polymorphisms and relationships between single genes will be an object of intensive research in next years.

Keywords: prostate cancer, genes, gene expression, polymorphisms, mutations, DNA, mRNA

Received: December 11, 2009; Accepted: March 26, 2010; Published: June 1, 2010 


Práce byla podpořena grantem GA UK 200 090.

Open full article

References

  1. Lesko SM, Rosenberg L, Shapiro S, et al. Family history and prostate cancer risk. Am J Epidemiol 1996; 144: 1041-1047. Go to original source... Go to PubMed...
  2. Lichtenstein P, Holm NV, Verkasalo PK, et al. Enviromental and heritable factors in the causation of cancer. Analyses of cohorts of twin from Sweden, Denmark and Finland. N Engl J Med 2000; 343: 78-85. Go to original source... Go to PubMed...
  3. Gillanders EM, Xu J, Chang BL, et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Nail Cancer Inst 2004; 96: 1240-1247. Go to original source... Go to PubMed...
  4. Cui J, Staples MP, Hopper JL, et al. Segregation analyses of 1,476 population-based Australian families affected by prostate cancer. Am J Hum Genet 2001; 68: 1207-1218. Go to original source... Go to PubMed...
  5. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996; 274: 1371-1374. Go to original source... Go to PubMed...
  6. Eeles RA, Durocher F, Carpten JD, et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet 1998; 62: 653-658. Go to original source... Go to PubMed...
  7. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry 2003; 42: 805-1812. Go to original source... Go to PubMed...
  8. Xiang Y, Wang Z, Murakami J, et al. Effects of RNaseL mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res 2003; 63: 6795-6801.
  9. Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev 2005; 14: 949-957. Go to original source... Go to PubMed...
  10. Maier C, Haeusler J, Herkommer K, et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 2005; 92: 1159-1164. Go to original source... Go to PubMed...
  11. Wiklund F, Jonsson BA, Brookes AJ, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 2004; 10: 7150-7156. Go to original source... Go to PubMed...
  12. Rennert H, Berkovich D, Hubert A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981-984. Go to original source... Go to PubMed...
  13. Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002; 70: 1299-1304. Go to original source... Go to PubMed...
  14. Goode EL, Stanford JL, Peters MA, et al. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res 2001; 7: 2739-2749.
  15. Fujiwara H, Emi M, Nagai H, et al. Association of common missense changes in ELAC2 (HPC2) with prostate cancer in a Japanese cas-control series. J Hum Genet 2002; 47: 641-648. Go to original source... Go to PubMed...
  16. Baffoe-Bonnie AB, Smith JR, Stephan DA, et al. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. J Hum Genet 2005; 117: 307-316. Go to original source... Go to PubMed...
  17. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophager scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002; 32: 321-325. Go to original source... Go to PubMed...
  18. De Winther MP, Gijbels MJ, Van Dijk KW, et al. Transgenic mouse models to study the role of the macrophage scavenger receptor class A in atherosclerosis. Int J Tissue React 2000; 22: 85-91.
  19. Bock CH, Cunningham JM, McDonnel SK, et al. Analysis of the prostate cancer-suspectibility locus HPC20 in 172 families affected by prostate cancer. Am J Hum Genet 2001; 68: 795-801. Go to original source... Go to PubMed...
  20. O'Neil LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol 2003; 24: 286-290. Go to original source... Go to PubMed...
  21. Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64: 2918-2922. Go to original source... Go to PubMed...
  22. Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism 1102V and the risk of prostate cancer in Finnish men. J Nail Cancer Inst 2003; 95: 812-818. Go to original source... Go to PubMed...
  23. Shih DM, Gu I, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998; 394: 284-287. Go to original source... Go to PubMed...
  24. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003; 72: 270-280. Go to original source... Go to PubMed...
  25. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867. Go to original source... Go to PubMed...
  26. Phillips SM, Barton CM, Lee SJ, et al. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994; 70: 1252-1257. Go to original source... Go to PubMed...
  27. Bowen C, Bubendorf L,Voeller HJ, et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res 2000; 60: 6111-6115.
  28. McMenamin ME, Soung P, Perera S, et al. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-4296.
  29. Suzuki H, Freije D, Nusskem DR, et al. Interfocal heterogenity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998; 58: 204-209.
  30. Kibel AS, Freije D, Isaacs WB, Bova GS, et al. Deletion mapping at 12p12-13 in metastatic prostate cancer. Genes Chromosomes Cancer 1999; 25: 270-276. Go to original source... Go to PubMed...
  31. Chen C, Hyytinen ER, Sun X, et al. Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am J Pathol 2003; 162: 1349-1354. Go to original source... Go to PubMed...
  32. Sun X, Frierson HF, Chen C, et al. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet 2005; 37: 407-412. Go to original source... Go to PubMed...
  33. Davoodpour P, Landstrom M,Welsh M. Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein. BMC Cancer 2007; 7: 161; http://www.biomedcentral.com/1471-2401/7/161. Go to original source... Go to PubMed...
  34. Irvine RA, Ma H, Yu MC, et al. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 2000; 9: 267-274. Go to original source... Go to PubMed...
  35. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGM repeat lengths in the androgen receptor gene and prostate cancer risk. A population-based case-control study in China. Cancer Res, 2000, 60: 5111-5116.
  36. Ford OH III, Gregory CW, Kim D, et al. Androgen receptor gene amplification and protein expression in recurrent prostate cancer. J Urol 2003; 170: 1817-1821. Go to original source... Go to PubMed...
  37. Buchanan G, Yang M, Cheong A, et al. Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet 2004; 13: 1677-1692. Go to original source... Go to PubMed...
  38. Chang B, Zheng SL, Isaacs SD, et al. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer 2001; 95: 354-359. Go to original source... Go to PubMed...
  39. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2,5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 2001; 57: 199-204. Go to original source... Go to PubMed...
  40. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosomes, indicates thousand of human genes are microRNA targets. Cell 2005; 120(1): 15-20. Go to original source... Go to PubMed...
  41. Collard RL, Harya NS, Monzon FA, Maier CE, O´Keefe DS. Methylation of the ASC Gene Promoter is Associated With Agressive Prostate Cancer. The Prostate 2006; 66: 687-695. Go to original source... Go to PubMed...
  42. Henrique R, Jeronimo C. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 2004; 46: 660-669. Go to original source... Go to PubMed...

Return to the content



Web časopisu Česká urologie je určen pouze pro lékaře a odborníky
z oblasti medicíny nebo farmacie.



Beru na vědomí, že informace zveřejněné na těchto stránkách
nejsou určeny pro laickou veřejnost.


Odejít Vstoupit